Ameriprise Financial Inc. Has $258.14 Million Position in Baxter International Inc. $BAX

Key Points

• Ameriprise Financial Inc. has increased its stake in Baxter International by 1.1%, bringing its total holdings to 7,540,942 shares, valued at $258.14 million.
• Baxter International's recent quarterly earnings missed analysts' expectations, reporting $0.59 EPS against a consensus estimate of $0.60, and revealing a revenue of $2.81 billion.
• Several brokerages have lowered their target prices for Baxter International stock, with Wells Fargo reducing it from $33.00 to $24.00 and Morgan Stanley decreasing it from $28.00 to $27.00.

Ameriprise Financial Inc. grew its holdings in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 1.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,540,942 shares of the medical instruments supplier's stock after acquiring an additional 83,973 shares during the period. Ameriprise Financial Inc. owned 1.47% of Baxter International worth $258,140,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Horizon Investments LLC grew its holdings in Baxter International by 5.0% during the 1st quarter. Horizon Investments LLC now owns 7,438 shares of the medical instruments supplier's stock worth $255,000 after acquiring an additional 351 shares during the period. Rothschild Investment LLC grew its stake in shares of Baxter International by 3.4% in the 1st quarter. Rothschild Investment LLC now owns 14,479 shares of the medical instruments supplier's stock valued at $496,000 after buying an additional 481 shares during the period. Archer Investment Corp grew its stake in shares of Baxter International by 20.5% in the 1st quarter. Archer Investment Corp now owns 2,935 shares of the medical instruments supplier's stock valued at $100,000 after buying an additional 500 shares during the period. Home Federal Bank of Tennessee grew its stake in shares of Baxter International by 2.5% in the 1st quarter. Home Federal Bank of Tennessee now owns 22,600 shares of the medical instruments supplier's stock valued at $774,000 after buying an additional 550 shares during the period. Finally, Private Trust Co. NA grew its stake in shares of Baxter International by 17.3% in the 1st quarter. Private Trust Co. NA now owns 3,822 shares of the medical instruments supplier's stock valued at $131,000 after buying an additional 565 shares during the period. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on BAX. Morgan Stanley reduced their target price on Baxter International from $28.00 to $27.00 and set an "underweight" rating for the company in a research note on Tuesday, July 15th. Wells Fargo & Company reduced their target price on Baxter International from $33.00 to $24.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Evercore ISI reduced their target price on Baxter International from $44.00 to $42.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Citigroup reduced their target price on Baxter International from $34.00 to $32.00 and set a "neutral" rating for the company in a research note on Wednesday, July 9th. Finally, Wall Street Zen downgraded Baxter International from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Three analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Baxter International currently has an average rating of "Hold" and an average price target of $30.11.

Baxter International Price Performance

BAX stock opened at $24.4950 on Friday. The company has a market capitalization of $12.58 billion, a P/E ratio of -81.65, a price-to-earnings-growth ratio of 0.78 and a beta of 0.59. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.49 and a current ratio of 2.30. Baxter International Inc. has a 52-week low of $21.33 and a 52-week high of $40.49. The business has a 50-day simple moving average of $27.46 and a two-hundred day simple moving average of $30.17.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.60 by ($0.01). The company had revenue of $2.81 billion for the quarter, compared to analyst estimates of $2.82 billion. Baxter International had a negative net margin of 1.42% and a positive return on equity of 16.96%. Baxter International's revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.68 EPS. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. Research analysts expect that Baxter International Inc. will post 2.48 EPS for the current fiscal year.

Baxter International Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Stockholders of record on Friday, August 29th will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Friday, August 29th. Baxter International's payout ratio is presently -226.67%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.